FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2462554540> ?p ?o ?g. }

• W2462554540 endingPage "2910" @default.
• W2462554540 startingPage "2901" @default.
• W2462554540 abstract "To evaluate the effect of secukinumab (interleukin-17A inhibitor) on patient-reported outcomes in patients with active ankylosing spondylitis (AS).In this phase III study, 371 patients were randomized (1:1:1) to receive intravenous (IV) secukinumab 10 mg/kg at baseline and weeks 2 and 4 followed by subcutaneous (SC) secukinumab 150 mg every 4 weeks (IV→150 mg group), or SC secukinumab 75 mg every 4 weeks (IV→75 mg group), or placebo. Patient-reported outcomes included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BASDAI criteria for 50% improvement (BASDAI 50), Short Form 36 (SF-36) physical component summary (PCS) score and mental component summary (MCS) score, Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire, Bath Ankylosing Spondylitis Functional Index (BASFI), EuroQol 5-domain (EQ-5D) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Work Productivity and Activity Impairment-General Health questionnaire (WPAI-GH).At week 16, secukinumab IV→150 mg or IV→75 mg was associated with statistically and clinically significant improvements from baseline versus placebo in the BASDAI (-2.3 for both regimens versus -0.6; P < 0.0001 and P < 0.001, respectively), SF-36 PCS (5.6 for both regimens versus 1.0; P < 0.0001 and P < 0.001, respectively), and ASQoL (-3.6 for both regimens versus -1.0; P < 0.0001 and P < 0.001, respectively). Clinically significant improvements in the SF-36 MCS, BASFI, EQ-5D, and BASDAI 50 were observed with both secukinumab groups versus placebo at week 16; improvements were also observed in the FACIT-F and WPAI-GH. All improvements were sustained through week 52.Our findings indicate that secukinumab provides significant and sustained improvements in patient-reported disease activity and health-related quality of life, and reduces functional impairment, fatigue, and impact of disease on work productivity in patients with active AS." @default.
• W2462554540 created "2016-07-22" @default.
• W2462554540 creator A5010897332 @default.
• W2462554540 creator A5015084747 @default.
• W2462554540 creator A5016651473 @default.
• W2462554540 creator A5017853281 @default.
• W2462554540 creator A5046625022 @default.
• W2462554540 creator A5053980996 @default.
• W2462554540 creator A5054434839 @default.
• W2462554540 creator A5060040374 @default.
• W2462554540 creator A5077099389 @default.
• W2462554540 date "2016-11-28" @default.
• W2462554540 modified "2023-10-12" @default.
• W2462554540 title "Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)" @default.
• W2462554540 cites W1502374914 @default.
• W2462554540 cites W1814526147 @default.
• W2462554540 cites W1873971385 @default.
• W2462554540 cites W1878264508 @default.
• W2462554540 cites W1964722637 @default.
• W2462554540 cites W1966756689 @default.
• W2462554540 cites W1966997770 @default.
• W2462554540 cites W1975594975 @default.
• W2462554540 cites W2014956394 @default.
• W2462554540 cites W2023652201 @default.
• W2462554540 cites W2024061449 @default.
• W2462554540 cites W2025124560 @default.
• W2462554540 cites W2042908517 @default.
• W2462554540 cites W2045870395 @default.
• W2462554540 cites W206355791 @default.
• W2462554540 cites W2063931484 @default.
• W2462554540 cites W2072322661 @default.
• W2462554540 cites W2084560920 @default.
• W2462554540 cites W2096092199 @default.
• W2462554540 cites W2099909375 @default.
• W2462554540 cites W2103649298 @default.
• W2462554540 cites W2103778140 @default.
• W2462554540 cites W2116785548 @default.
• W2462554540 cites W2118706017 @default.
• W2462554540 cites W2120676719 @default.
• W2462554540 cites W2124551692 @default.
• W2462554540 cites W2126477323 @default.
• W2462554540 cites W2127756765 @default.
• W2462554540 cites W2130082562 @default.
• W2462554540 cites W2137884440 @default.
• W2462554540 cites W2145993112 @default.
• W2462554540 cites W2153836018 @default.
• W2462554540 cites W2156371898 @default.
• W2462554540 cites W2159104463 @default.
• W2462554540 cites W2172285434 @default.
• W2462554540 cites W2278932593 @default.
• W2462554540 cites W2473786944 @default.
• W2462554540 cites W3135506742 @default.
• W2462554540 cites W4210974969 @default.
• W2462554540 doi "https://doi.org/10.1002/art.39805" @default.
• W2462554540 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5132041" @default.
• W2462554540 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27390130" @default.
• W2462554540 hasPublicationYear "2016" @default.
• W2462554540 type Work @default.
• W2462554540 sameAs 2462554540 @default.
• W2462554540 citedByCount "62" @default.
• W2462554540 countsByYear W24625545402017 @default.
• W2462554540 countsByYear W24625545402018 @default.
• W2462554540 countsByYear W24625545402019 @default.
• W2462554540 countsByYear W24625545402020 @default.
• W2462554540 countsByYear W24625545402021 @default.
• W2462554540 countsByYear W24625545402022 @default.
• W2462554540 countsByYear W24625545402023 @default.
• W2462554540 crossrefType "journal-article" @default.
• W2462554540 hasAuthorship W2462554540A5010897332 @default.
• W2462554540 hasAuthorship W2462554540A5015084747 @default.
• W2462554540 hasAuthorship W2462554540A5016651473 @default.
• W2462554540 hasAuthorship W2462554540A5017853281 @default.
• W2462554540 hasAuthorship W2462554540A5046625022 @default.
• W2462554540 hasAuthorship W2462554540A5053980996 @default.
• W2462554540 hasAuthorship W2462554540A5054434839 @default.
• W2462554540 hasAuthorship W2462554540A5060040374 @default.
• W2462554540 hasAuthorship W2462554540A5077099389 @default.
• W2462554540 hasBestOaLocation W24625545401 @default.
• W2462554540 hasConcept C126322002 @default.
• W2462554540 hasConcept C142724271 @default.
• W2462554540 hasConcept C1862650 @default.
• W2462554540 hasConcept C204787440 @default.
• W2462554540 hasConcept C27081682 @default.
• W2462554540 hasConcept C2776260265 @default.
• W2462554540 hasConcept C2777402515 @default.
• W2462554540 hasConcept C2777453003 @default.
• W2462554540 hasConcept C2777575956 @default.
• W2462554540 hasConcept C2779650986 @default.
• W2462554540 hasConcept C2779786854 @default.
• W2462554540 hasConcept C2780415856 @default.
• W2462554540 hasConcept C71924100 @default.
• W2462554540 hasConceptScore W2462554540C126322002 @default.
• W2462554540 hasConceptScore W2462554540C142724271 @default.
• W2462554540 hasConceptScore W2462554540C1862650 @default.
• W2462554540 hasConceptScore W2462554540C204787440 @default.
• W2462554540 hasConceptScore W2462554540C27081682 @default.
• W2462554540 hasConceptScore W2462554540C2776260265 @default.
• W2462554540 hasConceptScore W2462554540C2777402515 @default.

• next